Catalyst Event
Alnylam Pharmaceuticals Inc (ALNY) · Earnings Release
From KEDI U.S. Tech100 90% Participation + Daily Options Premium Index (KUSTC100P)
4/30/2026, 12:00:00 AM
Alnylam Q1 2026 financial results announcement, with an estimated market impact of ≥1% based on historical quarterly volatility, expected
Korean Translation
과거 분기별 변동성을 바탕으로 1% 이상의 시장 영향력이 예상되는 2026년 1분기 재무 실적 발표 예상됨
Related Recent Events
Broadcom Inc (AVGO) · Earnings Release
Q2 2026 earnings release on June 4, 2026; a Medium impact is estimated as quarterly earnings are key drivers of stock volatility, scheduled.
6/4/2026, 12:00:00 AM
Credo Technology Group Holding Ltd (CRDO) · Earnings Release
Next earnings release for Q4 fiscal 2026 on June 1, 2026, scheduled.
6/1/2026, 12:00:00 AM
Biogen Inc (BIIB) · Other
U.S. FDA PDUFA action date for the subcutaneous formulation of LEQEMBI for treatment initiation in early Alzheimer's disease is scheduled. This regulatory milestone is estimated to have a medium impact on stock price.
5/24/2026, 12:00:00 AM
Biogen Inc (BIIB) · Earnings Release
Biogen's Q1 2026 earnings release is expected around this date, based on past reporting schedules. Earnings releases typically result in moderate price volatility.
5/7/2026, 12:00:00 AM
Natera Inc (NTRA) · Earnings Release
Natera is expected to report its Q1 2026 earnings on May 7, 2026, with analysts forecasting an EPS of approximately -$0.55. Market impact is estimated at ≥1% as earnings dates are routine; scheduled.
5/7/2026, 12:00:00 AM
AppLovin Corporation (APP) · Earnings Release
AppLovin's Q1 2026 earnings release is scheduled.
5/6/2026, 12:00:00 AM